Trial Profile
Pharmacovigilence for Retapamulin: Age-stratified Monitoring of Prescribed Use in the European Union.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Sep 2023
Price :
$35
*
At a glance
- Drugs Retapamulin (Primary) ; Fusidic acid; Mupirocin
- Indications Bacterial infections; Impetigo
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 13 Apr 2012 Planned number of patients 1 added as reported by ClinicalTrials.gov.
- 07 Jul 2010 New trial record